{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:23:01Z","timestamp":1757618581337,"version":"3.44.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In Japan, adjuvant chemotherapy with docetaxel\/S-1 is recommended for stage III gastric cancer. However, this regimen may not be suitable for all patients due to toxicity and tolerability issues, particularly in older individuals or those with comorbidities. This study aimed to explore prognostic factors in stage IIIA gastric cancer and assess long-term outcomes in patients treated with S-1 monotherapy after curative gastrectomy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively analyzed 73 patients with stage IIIA gastric cancer (UICC 7th edition) who underwent curative gastrectomy and received postoperative adjuvant S-1 monotherapy between 2005 and 2018.Various prognostic factors, including preoperative (age, sex, BMI, tumor markers), perioperative (surgical approach, operative duration, blood loss, complications), and tumor-related variables (tumor size, lymph node status, histological features), were analyzed. Recurrence-free survival (RFS) was the primary endpoint, and cut-off values were determined using ROC analysis. Cox proportional hazards models were used for univariate and multivariate analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The 3- and 5-year RFS rates were 71.7% and 64.3%, respectively. Multivariate analysis identified smaller tumor size (\u2264\u200955.0\u00a0mm, <jats:italic>P<\/jats:italic>\u2009=\u20090.006) and lower lymph node positivity rate (\u2264\u20090.079, <jats:italic>P<\/jats:italic>\u2009=\u20090.008) as independent favorable prognostic factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>S-1 monotherapy may be associated with favorable long-term outcomes in selected patients with stage IIIA gastric cancer who have small tumors and low lymph node positivity rates. While these results are encouraging, they should not be interpreted as a rationale for broadly recommending S-1 monotherapy. Further studies are needed to define its role in individualized treatment strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00423-025-03781-x","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:58:46Z","timestamp":1752141526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of S-1 monotherapy in stage IIIA gastric cancer with small tumors and low nodal involvement"],"prefix":"10.1007","volume":"410","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9701-7604","authenticated-orcid":false,"given":"Tsunehiko","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiji","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"1","key":"3781_CR1","first-page":"21","volume":"88","author":"I Panzini","year":"2002","unstructured":"Panzini I, Gianni L, Fattori PP et al (2002) Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88(1):21\u201327","journal-title":"Tumori"},{"issue":"17","key":"3781_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.2010.534","volume":"303","author":"X Paoletti","year":"2010","unstructured":"Paoletti X, Oba K, Burzykowski T et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama 303(17):1729\u20131737","journal-title":"Jama"},{"issue":"10","key":"3781_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725\u2013730","journal-title":"N Engl J Med"},{"issue":"1","key":"3781_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11\u201320","journal-title":"N Engl J Med"},{"issue":"18","key":"3781_CR5","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810\u20131820","journal-title":"N Engl J Med"},{"issue":"12","key":"3781_CR6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 15(12):1389\u20131396","journal-title":"Lancet Oncol"},{"issue":"2","key":"3781_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10120-016-0606-4","volume":"20","author":"N Fuse","year":"2017","unstructured":"Fuse N, Bando H, Chin K et al (2017) Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Gastric Cancer 20(2):332\u2013340","journal-title":"Gastric Cancer"},{"issue":"1","key":"3781_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","volume":"20","author":"A Japanese Gastric Cancer","year":"2017","unstructured":"Japanese Gastric Cancer A (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20(1):1\u201319","journal-title":"Gastric Cancer"},{"issue":"5","key":"3781_CR9","doi-asserted-by":"publisher","first-page":"e28620","DOI":"10.1097\/MD.0000000000028620","volume":"101","author":"Y Li","year":"2022","unstructured":"Li Y, Zhao H (2022) Postoperative recurrence of gastric cancer depends on whether the chemotherapy cycle was more than 9 cycles: based on a retrospective and observational study of follow-up within 3 years of 843 patients. Med (Baltimore) 101(5):e28620","journal-title":"Med (Baltimore)"},{"issue":"15","key":"3781_CR10","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M et al (2019) Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 37(15):1296\u20131304","journal-title":"J Clin Oncol"},{"issue":"2","key":"3781_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205\u2013213","journal-title":"Ann Surg"},{"issue":"2","key":"3781_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s10120-013-0273-7","volume":"17","author":"K Fujitani","year":"2014","unstructured":"Fujitani K, Tamura S, Kimura Y et al (2014) Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer 17(2):348\u2013353","journal-title":"Gastric Cancer"},{"issue":"6","key":"3781_CR13","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10120-023-01419-9","volume":"26","author":"Y Kodera","year":"2023","unstructured":"Kodera Y, Yoshida K, Kochi M et al (2023) Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in stage III gastric cancer: a final report of the JACCRO GC-07 study. Gastric Cancer 26(6):1063\u20131068","journal-title":"Gastric Cancer"},{"issue":"7","key":"3781_CR14","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1245\/s10434-008-9884-3","volume":"15","author":"C Kunisaki","year":"2008","unstructured":"Kunisaki C, Makino H, Takagawa R et al (2008) Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol 15(7):1959\u20131967","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"3781_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.surg.2021.04.026","volume":"170","author":"DJ Erstad","year":"2021","unstructured":"Erstad DJ, Blum M, Estrella JS et al (2021) Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery 170(4):1231\u20131239","journal-title":"Surgery"},{"issue":"4","key":"3781_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000496746","volume":"42","author":"A Bilici","year":"2019","unstructured":"Bilici A, Selcukbiricik F, Seker M et al (2019) Prognostic significance of metastatic lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectomy. Oncol Res Treat 42(4):209\u2013216","journal-title":"Oncol Res Treat"},{"issue":"2","key":"3781_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s101200050034","volume":"2","author":"A Takagane","year":"1999","unstructured":"Takagane A, Terashima M, Abe K et al (1999) Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 2(2):122\u2013128","journal-title":"Gastric Cancer"},{"issue":"9","key":"3781_CR18","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1245\/ASO.2003.03.520","volume":"10","author":"D Nitti","year":"2019","unstructured":"Nitti D, Marchet A, Olivieri M et al (2003) Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 10(9):1077\u20131085","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3781_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(18)30383-2","volume":"4","author":"T Yoshikawa","year":"2019","unstructured":"Yoshikawa T, Terashima M, Mizusawa J et al (2019) Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol 4(3):208\u2013216","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-025-03781-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-025-03781-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-025-03781-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T03:50:33Z","timestamp":1757217033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-025-03781-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3781"],"URL":"https:\/\/doi.org\/10.1007\/s00423-025-03781-x","relation":{},"ISSN":["1435-2451"],"issn-type":[{"type":"electronic","value":"1435-2451"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest to declare in all authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of the Hitachi General Hospital (acceptance number 2019 \u2212\u2009100) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}